Skip to Main Content

The world is going to have to wait a little longer for the Merck Ebola vaccine.

Though Merck had repeatedly said it would file its licensure application with the Food and Drug Administration by the end of 2017, the company will not meet that self-imposed target, the team leader for the Ebola vaccine project told STAT on Friday.


“We have faced a number of challenges that have led to some delays. So we are not going to be able to make our December 2017 filing target that was frankly developed a number of years ago,” Beth-Ann Coller said in an interview.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!